BML 5.09 Increased By ▲ 0.03 (0.59%)
BOP 12.38 Increased By ▲ 0.52 (4.38%)
CNERGY 7.23 Increased By ▲ 0.04 (0.56%)
CPHL 87.05 Increased By ▲ 0.17 (0.2%)
DCL 14.86 Decreased By ▼ -0.09 (-0.6%)
DGKC 168.07 Decreased By ▼ -0.16 (-0.1%)
FCCL 46.25 Increased By ▲ 0.04 (0.09%)
FFL 16.03 Increased By ▲ 0.03 (0.19%)
GCIL 27.14 Increased By ▲ 0.01 (0.04%)
HUBC 141.50 Increased By ▲ 0.50 (0.35%)
KEL 5.14 Increased By ▲ 0.04 (0.78%)
KOSM 6.76 Increased By ▲ 0.11 (1.65%)
LOTCHEM 20.91 Decreased By ▼ -0.25 (-1.18%)
MLCF 84.50 Decreased By ▼ -0.43 (-0.51%)
NBP 120.35 Increased By ▲ 0.49 (0.41%)
PAEL 42.40 Increased By ▲ 0.43 (1.02%)
PIAHCLA 22.48 Decreased By ▼ -0.75 (-3.23%)
PIBTL 9.08 Increased By ▲ 0.21 (2.37%)
POWER 14.10 No Change ▼ 0.00 (0%)
PPL 169.40 Decreased By ▼ -1.52 (-0.89%)
PREMA 43.88 Decreased By ▼ -0.19 (-0.43%)
PRL 33.09 Increased By ▲ 0.05 (0.15%)
PTC 24.90 No Change ▼ 0.00 (0%)
SNGP 119.51 Increased By ▲ 0.17 (0.14%)
SSGC 45.41 Decreased By ▼ -0.12 (-0.26%)
TELE 8.22 Decreased By ▼ -0.08 (-0.96%)
TPLP 10.47 Decreased By ▼ -0.21 (-1.97%)
TREET 24.17 Decreased By ▼ -0.21 (-0.86%)
TRG 58.95 Increased By ▲ 1.09 (1.88%)
WTL 1.57 Decreased By ▼ -0.01 (-0.63%)
BR100 13,532 Increased By 70.1 (0.52%)
BR30 39,534 Increased By 3.2 (0.01%)
KSE100 133,294 Increased By 717.2 (0.54%)
KSE30 40,487 Increased By 127.9 (0.32%)

US FDA

US FDA expected to authorize Pfizer vaccine for 12-15-year-olds soon
World

US FDA expected to authorize Pfizer vaccine for 12-15-year-olds soon

  • The approval is highly anticipated after the drugmaker said in March the vaccine was found to be safe, effective and produced a robust antibody responses in 12- to 15-year-olds in a clinical trial.
  • The vaccine has already been cleared in the United States for those aged 16 and above.
Published 05 May, 2021 06:26pm
Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab
Business & Finance

Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

  • The request made to the US Food and Drug Administration is not due to any new safety issues, but in response to the new variants in the country that could be resistant to bamlanivimab when used alone, the drugmaker said in a statement.
  • Hospitals with bamlanivimab supply should now order etesevimab to pair with it, Lilly said.
Published 16 Apr, 2021 05:45pm